Literature DB >> 26302239

On the restricted mean survival time curve in survival analysis.

Lihui Zhao1, Brian Claggett2, Lu Tian3, Hajime Uno4, Marc A Pfeffer2, Scott D Solomon2, Lorenzo Trippa5,6, L J Wei6.   

Abstract

For a study with an event time as the endpoint, its survival function contains all the information regarding the temporal, stochastic profile of this outcome variable. The survival probability at a specific time point, say t, however, does not transparently capture the temporal profile of this endpoint up to t. An alternative is to use the restricted mean survival time (RMST) at time t to summarize the profile. The RMST is the mean survival time of all subjects in the study population followed up to t, and is simply the area under the survival curve up to t. The advantages of using such a quantification over the survival rate have been discussed in the setting of a fixed-time analysis. In this article, we generalize this approach by considering a curve based on the RMST over time as an alternative summary to the survival function. Inference, for instance, based on simultaneous confidence bands for a single RMST curve and also the difference between two RMST curves are proposed. The latter is informative for evaluating two groups under an equivalence or noninferiority setting, and quantifies the difference of two groups in a time scale. The proposal is illustrated with the data from two clinical trials, one from oncology and the other from cardiology.
© 2015, The International Biometric Society.

Entities:  

Keywords:  Equivalence/noninferiority study; Gaussian process; Martingale; Simultaneous confidence band; Survival function

Mesh:

Year:  2015        PMID: 26302239      PMCID: PMC5114026          DOI: 10.1111/biom.12384

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  14 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Efficient estimation of the distribution of quality-adjusted survival time.

Authors:  H Zhao; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

3.  Sequential methods for comparing years of life saved in the two-sample censored data problem.

Authors:  S Murray; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

4.  The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice.

Authors:  J O IRWIN
Journal:  J Hyg (Lond)       Date:  1949-06

5.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

6.  Calibrating parametric subject-specific risk estimation.

Authors:  T Cai; L Tian; Hajime Uno; Scott D Solomon; L J Wei
Journal:  Biometrika       Date:  2010-06       Impact factor: 2.445

7.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

8.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

9.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  55 in total

1.  How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Authors:  Miki Horiguchi; Michael J Hassett; Hajime Uno
Journal:  Oncologist       Date:  2018-09-10

2.  Colorectal Cancer Care Among Young Adult Patients After the Dependent Coverage Expansion Under the Affordable Care Act.

Authors:  Leticia Nogueira; Neetu Chawla; Xuesong Han; Ahmedin Jemal; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

3.  Adjusted restricted mean survival times in observational studies.

Authors:  Sarah C Conner; Lisa M Sullivan; Emelia J Benjamin; Michael P LaValley; Sandro Galea; Ludovic Trinquart
Journal:  Stat Med       Date:  2019-05-22       Impact factor: 2.373

4.  Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.

Authors:  Duy Ngo; Richard Baumgartner; Shahrul Mt-Isa; Dai Feng; Jie Chen; Patrick Schnell
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

5.  Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.

Authors:  Iván Díaz; Elizabeth Colantuoni; Daniel F Hanley; Michael Rosenblum
Journal:  Lifetime Data Anal       Date:  2018-02-28       Impact factor: 1.588

6.  A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.

Authors:  Milind A Phadnis; James B Wetmore; Matthew S Mayo
Journal:  Stat Med       Date:  2017-08-16       Impact factor: 2.373

7.  An Alternative Approach for the Analysis of Time-to-Event and Survival Outcomes in Pulmonary Medicine.

Authors:  Michael O Harhay; Raphaël Porcher; Edward Cantu; Michael J Crowther; Jason D Christie; Gabriel Thabut; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

8.  Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: A Decision Analysis.

Authors:  Sarah S Pickard; John B Wong; Emily M Bucholz; Jane W Newburger; Wayne Tworetzky; Terra Lafranchi; Carol B Benson; Louise E Wilkins-Haug; Diego Porras; Ryan Callahan; Kevin G Friedman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-04-07

9.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

10.  Analysis of restricted mean survival time for length-biased data.

Authors:  Chi Hyun Lee; Jing Ning; Yu Shen
Journal:  Biometrics       Date:  2017-09-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.